Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

NCT05199129 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1904-3
DRUG: RLD2001-1

Sponsor

Hanmi Pharmaceutical Company Limited